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Abstract
Objective Inappropriate prescribing and nonadherence have a significant impact
on hospital admissions and patient quality of life. The English government has iden-
tified that community pharmacy could make a significant contribution to reducing
nonadherence and improving the quality of prescribing, reducing both hospital
admissions and medicines wastage. The objective of this study is to evaluate a com-
munity pharmacy service aimed at patients over the age of 65 years prescribed four
or more medicines.
Methods Patients were invited to participate in the service by the community phar-
macy team. The pharmacist held regular consultations with the patient and dis-
cussed risk of falls, pain management, adherence and general health. They also
reviewed the patient’s medication using STOPP/START criteria.Data were analysed
for the first 6 months of participation in the service.
Keyfindings Sixhundred twentypatientswere recruitedwith441 (71.1%)complet-
ing the 6-month study period.Pharmacistsmade 142 recommendations to prescrib-
ers in 110 patients largely centred on potentially inappropriate prescribing of
NSAIDs,PPIs orduplicationof therapy.At follow-up, therewas a significantdecrease
in the totalnumberof falls (mean−0.116(−0.217–−0.014)) experiencedandasignifi-
cant increase inmedicine adherence (mean difference inMoriskyMeasure of Adher-
ence Scale-8: 0.513 (0.337–0.689)) and quality of life. Cost per quality-adjusted life
year estimates ranged from£11 885 to £32 466depending on the assumptionsmade.
Conclusion By focussing on patients over the age of 65 years with four or more
medicines, community pharmacists can improve medicine adherence and patient
quality of life.
Introduction
Almost 17.5 million people in the UK are believed to have a
long-term condition, the majority of whom will be pre-
scribedmedication.[1] Fifty-seven per cent of all prescriptions
dispensed in theUK in 2003were for people over the age of 60
with more than one-fifth of them prescribed five or more
medicines.[2] A Scottish study highlighted that the number of
regular medicines is strongly associated with unplanned hos-
pital admissions.[3] Some 35% of medicine-related admis-
sions to hospital have been attributed to inappropriate
prescribing[2] costing the National Health Service (NHS) an
estimated £750 million annually.[4] Additionally, as many as
30%ofmedicine-related hospital admissions occur as a result
of nonadherence to medication,[2] which has been estimated
to be as high as 30–50% in patients with long-term condi-
tions.[5] Consequently, evidence suggests that the return on
medicines investment is not optimised and could be
improved by enhancing the quality of prescribing and
increasing patient adherence.
The English government believes that community phar-
macists can contribute to supporting patient adherence and
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improving prescribing quality potentially resulting in
reduced hospital admissions.[6] Evidence suggests pharma-
cists can reduce inappropriate prescribing and adverse events,
encourage appropriate use of medicines by patients and
realise savings within the drugs’ budget.[7–10]
Medicine use reviews are delivered as one-off interven-
tions to patients prescribed medicines, mainly for long-term
conditions[11] and were introduced to reduce nonadherence.
There is currently limited, robust evidence demonstrating
the value of community pharmacy interventions particu-
larly with reference to health economic outcomes,[12] and
this is in line with many other interventions to improve
nonadherence.[13] It has recently been suggested that
longer-term behavioural-type interventions, where a rela-
tionship between the healthcare professional and patient
is developed and used to influence change, may be more
effective.[14]
Tools such as STOPP/START and the Beers’ criteria have
been developed to reduce inappropriate prescribing in a sys-
tematic manner.[15,16] Effective implementation of such tools
should ensure that prescribing is rationalised, adverse events
such as falls which lead to hospitalisation are minimised and
that patient quality of life is improved by limiting the use of
medicines known to cause sedation and confusion. Used by
pharmacists working in care homes to some effect,[4] they
have not been widely utilised within the community phar-
macy setting.
Inappropriate prescribing, monitoring and adherence
(particularly in the case of psychotropic medication) are all
contributing factors to the risk of falls experienced by this
group of patients. People over the age of 65 are more likely
to fall than any group in society with 30% estimated
to fall at least once per year.[17] The National Institute of
Health and Care Excellence has recommended that a patient
at risk of falls should undergo a multifactorial risk assess-
ment to identify areas that could be addressed to reduce
their risk of falling.[9] Targeting inappropriate psychotropic
and cardiovascular medication as part of a review along
with appropriate information regarding falls prevention has
been shown to help reduce the number of falls in older
people.[18–20]
Appropriate pain management is another area of concern
for this group of patients and is thought to affect many
patients over the age of 65 years.[21] It has been shown that in
patients with other co-morbidities, improving pain manage-
mentmay lead to improved outcomes for other conditions as
well as quality of life.[22]
The aim of this paper is to describe the effect of an holistic
community pharmacy-based service with patients over the
age of 65 years old and prescribed four or more medicines
(FOMM) which has been designed to improve both patient
adherence and prescribing quality using systematic tools to
standardise the intervention.
Methods
Nottingham NHS Research Ethics Committee deemed this
project a service evaluation, and therefore, formal ethical
approval was not required. The University of East Anglia’s
research ethics committee confirmed this. The FOMM
service was delivered from September 2012 to June 2013 and
located in Boots UK, Co-operative, Lloyds and Rowlands
pharmacies working together to design and implement at
their own cost.
Final service design was based on interventions which had
the opportunity to have the greatest impact on unplanned
hospitalisations, patient quality of life and that which a com-
munity pharmacist could provide without significant
re-training. These were poly-pharmacy, nonadherence, falls
risk and pain management, and had been determined from
patient need, best clinical practice, discussions with NHS
clinical leads for older people and operational experience.
Patients were invited to participate in the service via the
pharmacy or another healthcare professional (e.g. a general
practitioner (GP) could give the patient a leaflet that
explained the service) if they were over 65 years old and
taking FOMM. Prior to meeting with the patient, the phar-
macist conducted an assessment of their medication using
their pharmacy medication record (PMR) and STOPP/
START criteria. At the initial consultation, the pharmacist
discussed this assessment with the patient and agreed what
action should be taken in relation to contacting the GP. A
patient recordwas used as part of the service to direct the con-
sultation together with collecting the required data for evalu-
ation including all elements listed below.
For this service, a sub-set of the STOPP/START[23] criteria
was used that were appropriate for interventions made by
community pharmacists. Twenty-four of 65 (36.9%) of the
STOPP criteria and two of 22 of the START criteria were used
for this study. These were the criteria that community phar-
macists could sensibly assess without access to the patient’s
medical notes. These criteria were listed on the patient’s per-
sonal service record (designed to record relevant information
for the study and separate to the PMR) in order that the phar-
macist could assess their medication regime in an efficient
manner. If a particular criterion was present, then the phar-
macist ticked the box, and this prompted them tomake a rec-
ommendation to the GP.
They then asked specific questions relating to falls risk,
pain management and adherence, where appropriate. In
terms of falls risk, the pharmacist assessed the patient’smedi-
cation in a similar way to that of the STOPP/START criteria.
The patient record prompted the pharmacist to highlight
medicines that had an increased risk of causing falls. The
pharmacist then devoted a period of time during the initial
consultation to the discussion of falls risk. This included pre-
vious history of falls and other factors that might affect their
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risk. If necessary, the pharmacist then made recommenda-
tions to the patient about how tomitigate any risks including
advice on avoiding slips, trips and hazards, alcohol awareness,
and exercise advice. If the patient was identified as being at
risk of falls, then this was revisited and reviewedwith themon
a regular basis. The number of falls (self-reported) between
each review was recorded along with details regarding
whether it was self-treated or required medical attention.
The pharmacist assessed pain medication and their pain
score using scales recommended by the British Pain Society
and the British Geriatrics Society,[24] and, if necessary, then
provided follow-up advice to the patient and referred to the
GP as appropriate. Pain scores (scoring 1 (no pain) to 10
(worst pain imaginable)) and the effect it was having on their
daily activities (scoring 1 (not at all) to 10 (completely)) were
recorded. Finally, adherence was assessed at every appoint-
ment using the Morisky Measure of Adherence Scale
(MMAS-8),[24] and if appropriate, the pharmacist suggested
strategies to improve their medicine taking behaviour.
Where appropriate and throughout the entire interven-
tion, the pharmacist discussed, and referred to, any public
health interventions that might be useful to the patient (e.g.
smoking cessation, weight management or medicine use
review).The pharmacist discussed the STOPP/START assess-
ment with the patient’s GP if necessary. Patients then met
with the pharmacist on a regular basis depending on when
they collected their repeat medication or they felt a need. The
pharmacists made a decision in conjunction with the patient
regardingwhich sub-set of interventionswas appropriate and
which they were happy to receive (e.g. adherence, falls and/or
pain management).
This service was implemented in 25 community pharma-
cies in the Aston, Leigh and Wigan areas of England. These
areaswere chosen because they contained a similar number of
pharmacies from the four participating companies, and they
have a large population of older people. All the pharmacies
belonging to the four multiples within the localities were
included in the project. This included a range of locations,
and small and large pharmacies. The service was later rolled
out to other pharmacies within the locality (independents,
supermarkets).Datawere not collected from this latter group.
Pharmacists were trained via distance learning and face to
face, which included how to use the various different tools
and assessments. Training was then cascaded to other phar-
macy members.
To estimate the levels of health-related quality of life, par-
ticipants were asked to complete the EQ-5D-5L[25] at baseline
and at subsequent quarterly visits. Responses, which describe
the level of problems (ranging fromno problems to unable to
do) with regard to mobility, self-care, usual activities, pain
and anxiety/depression, were converted into a utility score (a
scale where death is equal to 0 and full health 1) using a
mapping approach based on the three-level version.[26]
Pharmacist time was estimated after discussion with par-
ticipating pharmacists at the end of the evaluation period.
Levels of resource use associatedwith the intervention (train-
ing, patient contacts (where initial monthly and quarterly
reviews were available)) and associated servicematerials were
recorded. Participants were also asked at (1) baseline (recall
period: previous 6 months) and (2) every subsequent visit
(recall period: since their last visit) to report the number of
the following items of other NHS resource use that were
received:
• GP visits
• Hospital admissions (and total number of days admitted, if
applicable)
• Accident and emergency (A&E) visits
• Hospital specialist consultation
• Out of hours contact with GP/nurse
Table 1 details the costs assigned to each of these items and
were estimated at 2011/2012 financial year levels.
All data for analysis were collected as part of service provi-
sion. Pharmacists were encouraged to use this data to struc-
ture the consultation with the patient. No additional data,
purely for the purposes of the evaluation,were collected from
patients.
Data analysis
To be included in the final analysis cohort, each patient was
required to meet the following criteria (where appropriate):
1. To have baseline data measured.
2. For the falls, pain and resource parameter analysis, to have
at least one follow-up consultation within 6 months ± 30
days to ensure that similar time horizons were being com-
pared pre and postintervention (i.e. baseline versus
follow-up). (Data collected during visits beyond this time
period were not included within the data analysis.)
Table 1 Unit costs attached to different items of resource use, with
associated source
Item
Estimated
unit cost (£)
Pharmacist (nonpatient contact time)* 50.00
Pharmacist (patient contact time)* 63.00
Healthcare assistant (cost per hour of employment) 12.50
GP visit* 43.00
Hospital admission (cost per day)† 254.00
Day case (weighted average of all procedures)† 680.70
A&E visit (not admitted cost)* 112.00
Hospital specialist consultation*** 139.00
Out of hours contact with GP/nurse# 53.58
A&E, accident and emergency; GP, general practitioner. *Taken from
Curtis.[27] †Taken from the National Schedule of Reference Costs.[28] #Esti-
mate based on a GP home visit lasting 11.4 min.[27] ***Assumed to
equate to weighted average of all out-patient procedures, taken from
Curtis.[27]
Michael Twigg et al. 409
International Journal of Pharmacy Practice 2015, 23, pp. 407--414 © 2015 The Authors. International Journal of Pharmacy Practice published by
John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society.
3. For adherence, patients for whom six monthly follow-up
consultations were available were included; providing the
sixth follow-up consultation fell within ±30 days from
baseline
4. For quality of life and in line with the complete case analy-
sis approach,[29] patients were only included if they had at
least one follow-up visit at 6 months ± 30 days where they
reported levels of resource use (if an EQ-5D scores, was
not also reported on this date, then the nearest follow-up
EQ-5D score to this date was used).
For the main analysis, once mean values had been derived
for each parameter before and after the pharmacy service
intervention, mean differences and associated confidence
intervals (CIs) were generated. The underlying assumption
was that the sampling distributions of the mean estimates
were normally distributed (though the distributions of
many of the parameters were skewed). The assumption of a
normal sampling distribution was made by applying the
central limit theorem which requires that samples in ques-
tion should have n > 30 patients. CIs associated with the
estimate of mean change which did not cross zero were
deemed to be statistically significant. No further analysis
was performed.
The total cost of the intervention was estimated by
summing the cost of the component parts (consultation,
training and service material costs). Total other NHS costs
were estimated by summing the costs associated with the
aforementioned self-report items of resource use. Total NHS
costs were estimated by summing the intervention and
total other NHS costs. Mean costs over the 6-month
preintervention period and the 6-month follow-up period
were subsequently estimated. The difference between these
two variables provided an estimate of the change in cost asso-
ciated with the intervention.
The area under the curve method[30] was used to estimate
the change in quality adjusted life year (QALY) score between
baseline and follow-up (the EQ-5D score was assumed to
change linearly).
If the mean estimated change in cost associated with the
intervention was positive along with the mean estimated
QALY change, then the incremental cost per QALY gain
(incremental cost-effectiveness ratio (ICER)) was calculated
(mean change in cost/meanQALY change).[31] Any calculated
ICER would be compared with a cost-effectiveness threshold
(λ) range of £20 000–30 000 per QALY.[31] Based on the cost-
effectiveness acceptability curve (CEAC),[32] we also report
the estimated probability of the intervention being cost-
effective at the λ values of £20 000 and £30 000 per QALY. A
further 12-month ICER was also calculated, where the
12-monthQALY change was estimated based on the assump-
tion that the EQ-5D score remained constant between the
6-month follow-up and 1 year; it was also assumed that no
further costs were incurred beyond the 6-month point.
Results
Six hundred twenty patients were enrolled in the service
(range 3–51 patients per pharmacy) and underwent an initial
assessment; 179 (28.9%) patients withdrew from the service
during the course of the evaluation period. The age distribu-
tion and number of medicines prescribed were approxi-
mately the same between those that completed the service
and those that withdrew. The most common reasons that
were stated for withdrawal were ‘lack of time’ (17.9%),
‘patient did not want to be bothered again’ (12.8%), ‘patient
had becomehousebound’(9.5%) and they felt they‘no longer
needed the service’ (6.1%). Of those initially registered,
51.0%were male, and themean (standard deviation) age was
73.9 (6.03). Patients registered for the service had a median
(IQ) number of conditions of 3 (2–4), and were taking a
median (IQ) 7 (5–9) medicines. Of these, the most common
conditions were cardiovascular, chronic pain, musculoskel-
etal and CHD.
Four hundred ninety-eight patients (80.3%) received the
STOPP/STARTassessment as part of their initial consultation
with the pharmacist. This resulted in 142 recommendations
being made across 110 (22.1%) patients. Table 2 illustrates
the type of recommendation made as a result of the STOPP/
START portion of the intervention.Of those 142 recommen-
dations, 35 (24.6%) were for an NSAID that had been
prescribed for longer than 3 months, 28 (19.7%) where a
proton pump inhibitor had been prescribed at maximum
therapeutic dosage for greater than 8 weeks, 25 (17.6%) cases
of duplication of therapy (six where the patient had been pre-
scribed more than one opioid) and 22 (15.5%) cases of
patients prescribed either an opioid or calcium channel
blocker with a tricyclic antidepressant.No data were collected
on implementation rate by the medical practice.
Table 3 provides the results for falls, pain and adherence
scores. There was a significant reduction (mean 0.116 (95%
CI, −0.217 to −0.014)) in the total number of falls. However,
there was no significant difference between baseline and
follow-up in the number of self-treated falls and those that
were medically treated. Pain scores over the course of the
evaluation period appeared to increase (nonsignificantly);
however, the effect of pain on day-to-day activities reduced
Table 2 STOPP/START recommendations
Measure Total
STOPP dose 5 (3.5%)
STOPP duration 70 (49.3%)
STOPP cautions 33 (23.2%)
STOPP duplication 25 (17.6%)
STOPP other 1 (0.7%)
START all 8 (5.6%)
Total 142
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over that same time frame. Adherence to medication
improved progressively over the course of the evaluation
period,with a significantly highermeanMMAS-8 score at the
end of the study.
A description of the resource use associated with the com-
ponent parts of the intervention is given in Table 4,where the
cost of the intervention was estimated to be £98.72 per par-
ticipant. A total of 339 (54.6%) participants had at least one
follow-up visit at 6 months ± 30 days. The levels of resource
use reported by these participants are summarised in Table 5,
where it can be seen that these are generally higher in the
6-month follow-up period compared with preintervention.
Overall, the mean (per participant) total other NHS costs
were higher in the 6-month follow-up period compared with
that preintervention (see Table 5), as was the total NHS cost
(when the intervention cost was included). Themean change
in total NHS cost associated with the intervention was esti-
mated to be £219.35 (95%CI, £167.91 to £273.19).
At the 6-month follow-up point, 249/339 (73.5%) patients
had the EQ-5D score performed on the same day as the
resource use data were recorded. The mean baseline, interim
(3-month) and 6-month follow-up EQ-5D scores were 0.733,
0.745 and 0.758, respectively. This equates to a mean change
in EQ-5D score of 0.025 (95% CI, 0.007 to 0.042) and an
Table 3 Falls, pain scores and adherence
Parameter n Measure Baseline Follow-up Difference (95% CI) Significant
Falls – total 303 Mean (SD) 0.251 (0.88) 0.135 (0.41) −0.116 (−0.217 to −0.014) Y
Falls – medical 303 Mean (SD) 0.092 (0.39) 0.053 (0.24) −0.040 (−0.089 to 0.010) N
Falls – self-treat 303 Mean (SD) 0.158 (0.76) 0.083 (0.32) −0.076 (−0.159 to 0.007) N
Pain score 264 Mean (SD) 3.561 (2.85) 3.682 (2.45) 0.121 (−0.084 to 0.327) N
Day-to-day activity 264 Mean (SD) 3.061 (2.87) 3.038 (2.40) −0.023 (−0.233 to 0.187) N
Adherence 115 Mean (SD) 7.348 (1.06) 7.861 (0.48) 0.513 (0.337 to 0.689) Y
Pain score, max score = 10 indicating worst pain imaginable; day-to-day activity, max score = 10 indicating complete interference with day-to-day activ-
ities; adherence score, max score = 8 indicating highly adherent.
Table 4 Intervention costs
Component part Resources costed (unit cost), participant costing
Mean cost
(£ per participant)
Training (receipt) Precourse distance learning (16 pharmacist hours) plus training course (2 h for pharmacist trainer and 8 h
for pharmacists trained) plus cascade training (1 h for pharmacists and 3 h for health care assistants)
(pharmacists £50 per hour*, health care assistant £12.50 per hour), divided across all n = 620
participants
2.24
Initial consultation 25-min patient contact time with pharmacist (£63 per hour*), n = 620 participants attended 26.25
Monthly review 10-min patient contact time with pharmacist (£63 per hour*), n = 1426 occurred in sample of 531 28.20
Quarterly review 11-min patient contact time with pharmacist (£63 per hour*), n = 1401 occurred in sample of 531 41.56
Equipment Four sets of service materials (@£75.00 each), divided across all n = 620 participants 0.48
Total 98.72
*Taken from Curtis.[27] Estimated within study costs.
Table 5 Per participant mean (range) levels of resource use and associated costs (n = 339 responders)
Item
Levels of resource use Mean cost (£)
Preintervention
6-month
follow-up Difference
Preintervention
(£)
6-month
follow-up (£)
Difference
(£)
GP visits 1.65 2.04 0.39 70.91 87.65 16.74
Number of hospital admissions 0.04 0.14 0.09 – – –
Total number of days in hospital 0.17 0.29 0.12 49.54 90.85 41.31
A&E visit 0.07 0.07 −0.00 7.93 7.60 −0.33
Hospital specialist consultation 0.36 0.72 0.37 49.61 100.46 50.84
Out of hours contact 0.03 0.05 0.02 1.42 2.43 1.11
Total other NHS costs 179.41 289.08 109.67
Intervention costs 0.00 109.67 109.67
Total NHS costs 179.41 398.76 219.35
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estimated change in QALY of 0.007 at 6-month follow-up
(95% CI, 0.001 to 0.012). The 6-month ICER was estimated
to be £32 466.03 (£219.35/0.007), slightly outside the often
quoted value for money threshold of £30 000 per QALY.[31]
Based on the CEAC, at £20 000 per QALY, the probability of
being cost-effective was 13.8%, compared with 43.5% at
£30 000 per QALY. Based on the 12-month QALY gain, the
ICER would be estimated to be £11 885.18 (£219.35/0.018),
with probabilities of 81.0% and 90.5%, respectively.
Discussion
This service evaluation has demonstrated that in patients pre-
scribed FOMM, a community pharmacist intervention is
associated with positive outcomes in patients over the age of
65 years. A significant reduction in the total number of
reported falls together with a significant improvement in
adherence to medicines and quality of life was seen. It also
demonstrated that the service had the potential to be cost-
effective (if the 6-month gains weremaintained at 12months
at no further cost).
The strengths of this independently evaluated project were
that it recruited a large number of patients and providers and
therefore is likely to be generalisable. The intervention used
standardised and validated tools to assess prescribing, adher-
ence and quality of life and formed the basis for the consulta-
tions with patients in a naturalistic setting. This appears to
have been beneficial as the service managed to retain a large
number of patients for the duration of the intervention.
The main criticism of this project is that it is a before-and-
after analysis, and from this,we cannot rule out the possibility
that any improvement was due to external influences. It must
also be assumed that some proportion of the patients would
have been actively reviewed by their GP in the same time
period. An attrition rate of just over a quarter of participants
requires further research to better understand why patients
chose to not continue with a service being provided by their
regular pharmacist.A further limitation of this studywas that
it was not powered to detect significant differences in out-
comes at the outset. A post-hoc power calculation was also
not conducted.
This evaluation needed to report back in a timely fashion
to inform pharmacy service development. As such, no
follow-up data were collected after the end of the 6-month
evaluation period, and as such, no inferences can be made
about the long-term effect of such a service and whether the
interaction with the pharmacist needs to continue on a
regular basis to maintain its effect on the outcomes
measured.
Adherence was characterised using a self-report method
which may be less reliable than other forms of adherence
measurement (e.g. prescription refill data[33]), and the act of
completing the questionnaire may have had an effect on this
result. However, this would have been the case at both base-
line and follow-up, and the size of the effect seen is large, and
therefore, it would seem prudent to assume that much of
what was seen was as a result of the intervention. As patients
are also free to obtain theirmedicines from any pharmacy,we
could not be confident that refill data, based on a single phar-
macy patient medication record, would be robust enough to
be a measure of adherence. In this context, adherence was
only used to explain any improvements in clinical outcomes.
Another limitation is that data regarding the implementation
rate of recommendationsmade to the GPwere not character-
ised. Again, for this evaluation, this was only used to explain
any improvements in clinical outcomes.
The findings from this evaluation appear to support the
suggestion that community pharmacists can achieve the same
outcomes as pharmacists working in care homes,with respect
to a reduction in the number of falls after medication
review.[34] Thismay largely be due to the review of medication
using a standardised tool which identified a number of cases
where inappropriate therapy could have been linked to the
increased likelihood of falling (e.g. duplication of opioid
analgesics or tricyclic antidepressants prescribed with an
opioid).
In the short term, this interventionmay have resulted in an
increase in referrals to the GP to alter medications as a result
of the STOPP/START criteria. However, if this service was
conducted by a supplementary prescribing pharmacist,
working within a clinical management plan cost savings may
be realised. This collaborative approach between the medical
practice and community pharmacy may be preferred by
patients where services are seen to be an extension of the
usual care from their GP rather than as an independent
add-on.[35]
This service included an average of 7.2 consultations
between patients and their pharmacist (based on those in
the final analysis), and this appears to have been useful at
reducing nonadherence. With a positive relationship with
healthcare professionals a predictor of improved adher-
ence,[36] thismay explain this finding.While evidence suggests
that reducing nonadherence improves patient outcomes,[37]
no effect on hospitalisation or pain control was seen. This
may be again due to the relatively short time period for
follow-up in this study, and perhaps data from 12 months
may have provided amore complete picture. The appropriate
use of medicines and increased adherence this service may
also have had an impact on reducing medicines wastage
although data on this were not captured. Quality of life
appeared to increase as a result of this intervention; however,
it cannot be determined which aspect of the service contrib-
uted to this increase.
The emphasis on polypharmacy, defined as taking
FOMM,[2,21] along with an approach that focuses on the
patient rather than a specific guideline-driven disease state,
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is something that has been recently advocated in the
literature[38,39] and is now the focus of a consultation into a
revision to the current GP incentive scheme.[40] Pharmacists
who participated in this service have demonstrated that when
provided with a service specification and protocol to follow,
they can have a significant effect on patient care.
Conclusion
By providing a multidimensional, patient-focused interven-
tion,pharmacists were able to demonstrate positive outcomes
in relation to quality of life, adherence and risk reduction.
This was a multiconsultation service that aimed to build a
relationship with the patient. The intervention was estimated
to be associated with a mean cost increase of £219.35 to the
NHS and a mean QALY gain of 0.007. The intervention was
shown to have the potential to be cost-effective if these
increases can bemaintained at no further cost, though due to
the before and after nature of the analysis, these results should
be treated with caution.
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